Noxopharm
Delivering Science. Transforming Lives.
Learn more

upcoming events

Noxopharm 2021 AGM

SHARE PRICE

Mkt Cap:
Noxopharm is pioneering life-changing therapies through innovative science.
WHO WE ARE
We are an Australian clinical-stage drug development company, founded in 2015. Noxopharm's drug development pipeline is focused on developing new treatment options for a broad range of solid tumour cancers and septic shock. Both areas of unmet medical need.
Noxopharm's current lead drug candidate is Veyonda®, currently being tested in several cancer trials, and also in at-risk COVID-19 patients, for its ability to harness the power of the immune system.
FOUR R&D BUSINESSES IN ONE COMPANY
Cancer Research
Pipeline
Veyonda®
Noxopharm Corporate Video
Media Centre
 
Noxopharm continually strives to communicate clearly, frequently and comprehensively with the market and our collaborators.